Assessment Status | Rapid Review complete |
HTA ID | 22033 |
Drug | Cholecalciferol |
Brand | Egostar® |
Indication | Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
Assessment Process | |
Rapid review commissioned | 11/05/2022 |
Rapid review completed | 23/06/2022 |
Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Egostar® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.